Search
for
Sort by
Research 30 of 1000+
- Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
- 1373 Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
- Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy
- 183 PD-1 regulatory network is upregulated in contact immunotherapy during alopecia areata treatment
- A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy
- The role of lymphocytes in the development and treatment of alopecia areata
- ISID1373 - Expression of programmed cell death 1 inversely correlated with the density of CD8+ T cells infiltrating hair follicles in alopecia areata
- Anti-programmed cell death protein 1-induced lichenoid changes of the nail unit: Histopathologic description
- Tregs: Where We Are and What Comes Next?
- Immunosenescence and inflammaging in Parkinson’s disease: mechanisms and therapeutic prospects
- N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma
- Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
- Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
- Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- From basic biology to engineered therapies: the keratinocyte stem cell playbook
- Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management
- Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment
- Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells
- Dermatologic Adverse Events from Cancer Treatments
- Management of Toxicities of Targeted Therapies
- Industry update: the latest developments in the field of therapeutic delivery, July 2018
- The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database